InDevR, Inc., a Boulder, CO-based biotechnology company focused on developing and commercializing novel analytical technologies for biologic process development and monitoring, raised $7m in Series A round of equity financing.
Adjuvant Capital made the investment.
The company intends to use the funds to conduct research and development activities and to build out the global commercial enterprise.
Led by Dr. Kathy Rowlen, CEO and co-founder, InDevR is a biotechnology company providing new protein characterization tools to impact vaccine process optimization and manufacturing.
With a history of non-dilutive funding raises, including a $14.7M BARDA contract to develop a high information content influenza diagnostic and recent investment from the Bill & Melinda Gates Foundation to advance measles and rubella vaccine characterization, InDevR has launched several life science tool-based product lines including:
– The VaxArray® Influenza vaccine potency testing system based on a multiplexed immunoassay and
– the Cypher One analyzer, which provides automated imaging and interpretation of hemagglutination and hemagglutination inhibition assays.